{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T21:19:00Z","timestamp":1767993540366,"version":"3.49.0"},"reference-count":84,"publisher":"Hindawi Limited","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1339,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1111\/j.1529-8019.2012.01497.x","type":"journal-article","created":{"date-parts":[[2012,5,16]],"date-time":"2012-05-16T14:37:26Z","timestamp":1337179046000},"page":"23-37","source":"Crossref","is-referenced-by-count":25,"title":["New antibiotic therapies for acne and rosacea"],"prefix":"10.1155","volume":"25","author":[{"given":"RANA MAJD","family":"MAYS","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"RACHEL A.","family":"GORDON","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JANICE M.","family":"WILSON","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SIRUNYA","family":"SILAPUNT","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2012,5,16]]},"reference":[{"issue":"10","key":"10.1111\/j.1529-8019.2012.01497.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1600-0625.2009.00890.x","article-title":"New developments in our understanding of acne pathogenesis and treatment","volume":"18","author":"Kurokawa","year":"2009","journal-title":"Exp Dermatol"},{"issue":"5","key":"10.1111\/j.1529-8019.2012.01497.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.clindermatol.2004.03.006","article-title":"Acne: inflammation","volume":"22","author":"Farrar","year":"2004","journal-title":"Clin Dermatol"},{"issue":"3","key":"10.1111\/j.1529-8019.2012.01497.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.sder.2008.07.001","article-title":"Antibiotic treatment for acne vulgaris","volume":"27","author":"Webster","year":"2008","journal-title":"Semin Cutan Med Surg"},{"issue":"15","key":"10.1111\/j.1529-8019.2012.01497.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.2165\/00003495-200363150-00005","article-title":"Current concepts of the pathogenesis of acne: implications for drug treatment","volume":"63","author":"Gollnick","year":"2003","journal-title":"Drugs"},{"issue":"2","key":"10.1111\/j.1529-8019.2012.01497.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.phrs.2010.10.007","article-title":"Clinical applications of non-antimicrobial tetracyclines in dermatology","volume":"63","author":"Monk","year":"2011","journal-title":"Pharmacol Res"},{"issue":"4","key":"10.1111\/j.1529-8019.2012.01497.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1001\/archderm.139.4.459","article-title":"Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne","volume":"139","author":"Skidmore","year":"2003","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1111\/j.1529-8019.2012.01497.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.clindermatol.2004.03.002","article-title":"Guidelines for treating acne","volume":"22","author":"Katsambas","year":"2004","journal-title":"Clin Dermatol"},{"issue":"2","key":"10.1111\/j.1529-8019.2012.01497.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jaad.2005.10.004","article-title":"Tetracyclines: nonantibiotic properties and their clinical implications","volume":"54","author":"Sapadin","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1111\/j.1529-8019.2012.01497.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.clindermatol.2004.03.009","article-title":"Acne: topical treatment","volume":"22","author":"Krautheim","year":"2004","journal-title":"Clin Dermatol"},{"issue":"8","key":"10.1111\/j.1529-8019.2012.01497.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1001\/archdermatol.2011.67","article-title":"Antibiotics, acne, and Staphylococcus aureus colonization","volume":"147","author":"Fanelli","year":"2011","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1111\/j.1529-8019.2012.01497.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1001\/archderm.139.4.467","article-title":"Effect of antibiotics on the oropharyngeal flora in patients with acne","volume":"139","author":"Levy","year":"2003","journal-title":"Arch Dermatol"},{"issue":"8","key":"10.1111\/j.1529-8019.2012.01497.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/archdermatol.2011.201","article-title":"Dermatologists do not yet fully understand the clinical significance of antibiotic use and bacterial resistance in patients with acne: comment on \u201cAntibiotics, acne, and Staphylococcus aureus colonization.\u201d","volume":"147","author":"Thiboutot","year":"2011","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1111\/j.1529-8019.2012.01497.x-BIB13|cit13","first-page":"532","article-title":"Is topical dapsone safe in glucose-6-phosphate dehydrogenase-deficient and sulfonamide-allergic patients?","volume":"9","author":"Webster","year":"2010","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"10.1111\/j.1529-8019.2012.01497.x-BIB14|cit14","first-page":"667","article-title":"Harnessing the anti-inflammatory effects of topical dapsone for management of acne","volume":"9","author":"Kircik","year":"2010","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"10.1111\/j.1529-8019.2012.01497.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/MOP.0b013e3283425457","article-title":"Changing the topography of acne with topical medications","volume":"23","author":"Imahiyerobo-Ip","year":"2011","journal-title":"Curr Opin Pediatr"},{"issue":"6","key":"10.1111\/j.1529-8019.2012.01497.x-BIB16|cit16","first-page":"607","article-title":"Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris","volume":"6","author":"Schlessinger","year":"2007","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"10.1111\/j.1529-8019.2012.01497.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1365-2133.2000.03701.x","article-title":"A multicentre, single-blind, randomized comparison of a fixed clindamycin phosphate\/tretinoin gel formulation (Velac) applied once daily and a clindamycin lotion formulation (Dalacin T) applied twice daily in the topical treatment of acne vulgaris","volume":"143","author":"Zouboulis","year":"2000","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1111\/j.1529-8019.2012.01497.x-BIB18|cit18","first-page":"131","article-title":"A randomized, investigator-blinded trial to assess the antimicrobial efficacy of a benzoyl peroxide 5%\/clindamycin phosphate 1% gel compared with a clindamycin phosphate 1.2%\/tretinoin 0.025% gel in the topical treatment of acne vulgaris","volume":"9","author":"Jackson","year":"2010","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"10.1111\/j.1529-8019.2012.01497.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jaad.2005.04.046","article-title":"Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin\/tretinoin hydrogel with each agent alone and vehicle for the treatment of acne vulgaris","volume":"54","author":"Leyden","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1111\/j.1529-8019.2012.01497.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0926-9959(98)00071-3","article-title":"Efficacy of the fixed 1.2% clindamycin phosphate, 0.025% tretinoin gel formulation (Velac) and a proprietary 0.025% tretinoin gel formulation (Aberela) in the topical control of facial acne","volume":"11","author":"Richter","year":"1998","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1111\/j.1529-8019.2012.01497.x-BIB21|cit21","first-page":"383","article-title":"Tolerability of clindamycin\/tretinoin gel vs. tretinoin microsphere gel and adapalene gel","volume":"8","author":"Leyden","year":"2009","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"10.1111\/j.1529-8019.2012.01497.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/S0190-9622(97)70177-4","article-title":"Treatment of acne with a combination clindamycin\/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations","volume":"37","author":"Lookingbill","year":"1997","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1111\/j.1529-8019.2012.01497.x-BIB23|cit23","first-page":"164","article-title":"Clinical experience results with clindamycin 1% benzoyl peroxide 5% gel (Duac) as monotherapy and in combination","volume":"4","author":"Bikowski","year":"2005","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"10.1111\/j.1529-8019.2012.01497.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1365-2133.2007.08308.x","article-title":"A randomized, single-blind comparison of topical clindamycin + benzoyl peroxide and adapalene in the treatment of mild to moderate facial acne vulgaris","volume":"158","author":"Langner","year":"2008","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1111\/j.1529-8019.2012.01497.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2165\/00128071-200809050-00005","article-title":"Comparative irritation potential of two combination acne products: a randomized controlled, subject- and evaluator-blind, comparative study in healthy volunteers","volume":"9","author":"Dosik","year":"2008","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"10.1111\/j.1529-8019.2012.01497.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1016\/j.jaad.2011.03.014","article-title":"Meta-analysis of randomized controlled trials using 5% benzoyl peroxide and clindamycin versus 2.5% benzoyl peroxide and clindamycin topical treatments in acne","volume":"65","author":"Seidler","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1111\/j.1529-8019.2012.01497.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2165\/00128071-200405040-00005","article-title":"Benzoyl peroxide-based combination therapies for acne vulgaris: a comparative review","volume":"5","author":"Taylor","year":"2004","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"10.1111\/j.1529-8019.2012.01497.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/120347540100500109","article-title":"The efficacy and safety of a combination benzoyl peroxide\/clindamycin topical gel compared with benzoyl peroxide alone and a benzoyl peroxide\/erythromycin combination product","volume":"5","author":"Leyden","year":"2001","journal-title":"J Cutan Med Surg"},{"issue":"5","key":"10.1111\/j.1529-8019.2012.01497.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0149-2918(02)85151-7","article-title":"A randomized, parallel, vehicle-controlled comparison of two erythromycin\/benzoyl peroxide preparations for acne vulgaris","volume":"24","author":"Thiboutot","year":"2002","journal-title":"Clin Ther"},{"issue":"12","key":"10.1111\/j.1529-8019.2012.01497.x-BIB30|cit30","first-page":"1149","article-title":"Subantimicrobial-dose doxycycline in the treatment of moderate facial acne","volume":"7","author":"Toossi","year":"2008","journal-title":"J Drugs Dermatol"},{"issue":"11","key":"10.1111\/j.1529-8019.2012.01497.x-BIB31|cit31","first-page":"1407","article-title":"Doxycycline and minocycline for the management of acne: a review of efficacy and safety with emphasis on clinical implications","volume":"9","author":"Kircik","year":"2010","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"10.1111\/j.1529-8019.2012.01497.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/j.1552-4604.1988.tb03160.x","article-title":"A double-blind, multiple-dose, placebo-controlled, cross-over study to compare the incidence of gastrointestinal complaints in healthy subjects given Doryx R and Vibramycin R","volume":"28","author":"Berger","year":"1988","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/j.1529-8019.2012.01497.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2165\/00044011-199510060-00002","article-title":"Enteric coating reduces upper gastrointestinal adverse reactions to doxycycline","volume":"10","author":"Jarvinen","year":"1995","journal-title":"Clin Drug Investig"},{"issue":"5","key":"10.1111\/j.1529-8019.2012.01497.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/ebch.857","article-title":"Commentaries on \u201cMinocycline for acne vulgaris: efficacy and safety\u201d with a response from the review authors","volume":"6","author":"Del Rosso","year":"2011","journal-title":"Evid Based Child Health"},{"issue":"1","key":"10.1111\/j.1529-8019.2012.01497.x-BIB35|cit35","first-page":"44","article-title":"Weight-based dosing and extended-release formulation of minocycline tablets: is there clinical significance?","volume":"2","author":"Del Rosso","year":"2009","journal-title":"J Clin Aesthet Dermatol"},{"issue":"4","key":"10.1111\/j.1529-8019.2012.01497.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/09546630600866459","article-title":"Azithromycin versus tetracycline in the treatment of acne vulgaris","volume":"17","author":"Rafiei","year":"2006","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"10.1111\/j.1529-8019.2012.01497.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1365-2230.2005.01769.x","article-title":"Comparison of efficacy of azithromycin vs. doxycycline in the treatment of acne vulgaris","volume":"30","author":"Kus","year":"2005","journal-title":"Clin Exp Dermatol"},{"issue":"10","key":"10.1111\/j.1529-8019.2012.01497.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1365-4632.2004.02058.x","article-title":"Acne treated successfully with azithromycin","volume":"43","author":"Kapadia","year":"2004","journal-title":"Int J Dermatol"},{"issue":"9","key":"10.1111\/j.1529-8019.2012.01497.x-BIB39|cit39","first-page":"873","article-title":"Common and alternate oral antibiotic therapies for acne vulgaris: a review","volume":"6","author":"Amin","year":"2007","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"10.1111\/j.1529-8019.2012.01497.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1365-4362.1997.tb04199.x","article-title":"Azithromycin for the treatment of acne","volume":"36","author":"Fernandez-Obregon","year":"1997","journal-title":"Int J Dermatol"},{"issue":"4","key":"10.1111\/j.1529-8019.2012.01497.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1080\/09546630701881506","article-title":"Azithromycin pulses in the treatment of inflammatory and pustular acne: efficacy, tolerability and safety","volume":"19","author":"Antonio","year":"2008","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"10.1111\/j.1529-8019.2012.01497.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1346-8138.2001.tb00077.x","article-title":"Azithromycin monthly pulse vs. daily doxycycline in the treatment of acne vulgaris","volume":"28","author":"Parsad","year":"2001","journal-title":"J Dermatol"},{"issue":"4","key":"10.1111\/j.1529-8019.2012.01497.x-BIB43|cit43","first-page":"274","article-title":"Comparison of oral azithromycin pulse with daily doxycycline in the treatment of acne vulgaris","volume":"69","author":"Singhi","year":"2003","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"4","key":"10.1111\/j.1529-8019.2012.01497.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3109\/09546631003762639","article-title":"Comparison of therapeutic effects of oral doxycycline and azithromycin in patients with moderate acne vulgaris: what is the role of age?","volume":"22","author":"Babaeinejad","year":"2011","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"10.1111\/j.1529-8019.2012.01497.x-BIB45|cit45","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1179\/joc.1998.10.6.469","article-title":"Azithromycin compared with minocycline in the treatment of acne comedonica and papulo-pustulosa","volume":"10","author":"Gruber","year":"1998","journal-title":"J Chemother"},{"issue":"4","key":"10.1111\/j.1529-8019.2012.01497.x-BIB46|cit46","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5070\/D33QF1X5T6","article-title":"Azithromycin: a new therapeutical strategy for acne in adolescents","volume":"13","author":"Bardazzi","year":"2007","journal-title":"Dermatol Online J"},{"issue":"1","key":"10.1111\/j.1529-8019.2012.01497.x-BIB47|cit47","first-page":"13","article-title":"Moderate acne vulgaris: efficacy, tolerance and compliance of oral azithromycin thrice weekly for","volume":"16","author":"Innocenzi","year":"2008","journal-title":"Acta Dermatovenerol Croat"},{"issue":"5","key":"10.1111\/j.1529-8019.2012.01497.x-BIB48|cit48","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1046\/j.1468-3083.2000.00086-2.x","article-title":"A novel treatment for acne vulgaris and rosacea","volume":"14","author":"Elewski","year":"2000","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"10.1111\/j.1529-8019.2012.01497.x-BIB49|cit49","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/j.1365-4632.2010.04506.x","article-title":"In vitro antimicrobial susceptibility of Propionibacterium acnes isolated from acne patients in northern Mexico","volume":"49","author":"Gonz\u00e1lez","year":"2010","journal-title":"Int J Dermatol"},{"issue":"3","key":"10.1111\/j.1529-8019.2012.01497.x-BIB50|cit50","first-page":"156","article-title":"The treatment of acne vulgaris with low dosage doxycycline","volume":"13","author":"Parish","year":"2005","journal-title":"Acta Dermatovenerol Croat"},{"issue":"2","key":"10.1111\/j.1529-8019.2012.01497.x-BIB51|cit51","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1525-1470.2008.00628.x","article-title":"Oral cephalexin for acne vulgaris: clinical experience with 93 patients","volume":"25","author":"Fenner","year":"2008","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"10.1111\/j.1529-8019.2012.01497.x-BIB52|cit52","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S0190-9622(86)80190-6","article-title":"Cephalosporin for acne vulgaris","volume":"14","author":"Sheeler","year":"1986","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1111\/j.1529-8019.2012.01497.x-BIB53|cit53","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1159\/000063365","article-title":"Levofloxacin is effective for inflammatory acne and achieves high levels in the lesions: an open study","volume":"204","author":"Kawada","year":"2002","journal-title":"Dermatology"},{"issue":"12","key":"10.1111\/j.1529-8019.2012.01497.x-BIB54|cit54","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1128\/AAC.00672-07","article-title":"Activity of the novel macrolide BAL19403 against ribosomes from erythromycin-resistant Propionibacterium acnes","volume":"51","author":"Dreier","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1111\/j.1529-8019.2012.01497.x-BIB55|cit55","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1128\/AAC.00062-07","article-title":"Antipropionibacterial activity of BAL19403, a novel macrolide antibiotic","volume":"51","author":"Heller","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1111\/j.1529-8019.2012.01497.x-BIB56|cit56","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1128\/AAC.00561-11","article-title":"In vitro antibacterial activity of NB-003 against Propionibacterium acnes","volume":"55","author":"Pannu","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1111\/j.1529-8019.2012.01497.x-BIB57|cit57","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00005-006-0007-1","article-title":"Susceptibility of Propionibacterium acnes and Staphylococcus epidermidis to killing by MPO-halide system products. Implication for taurine bromamine as a new candidate for topical therapy in treating acne vulgaris","volume":"54","author":"Marcinkiewicz","year":"2006","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"4","key":"10.1111\/j.1529-8019.2012.01497.x-BIB58|cit58","first-page":"433","article-title":"Topical taurine bromamine, a new candidate in the treatment of moderate inflammatory acne vulgaris: a pilot study","volume":"18","author":"Marcinkiewicz","year":"2008","journal-title":"Eur J Dermatol"},{"issue":"5","key":"10.1111\/j.1529-8019.2012.01497.x-BIB59|cit59","doi-asserted-by":"crossref","first-page":"440","DOI":"10.4161\/viru.1.5.12983","article-title":"Antimicrobial peptides: the ancient arm of the human immune system","volume":"1","author":"Wiesner","year":"2010","journal-title":"Virulence"},{"issue":"4","key":"10.1111\/j.1529-8019.2012.01497.x-BIB60|cit60","first-page":"358","article-title":"The efficacy of topical 2% green tea lotion in mild-to-moderate acne vulgaris","volume":"8","author":"Elsaie","year":"2009","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"10.1111\/j.1529-8019.2012.01497.x-BIB61|cit61","doi-asserted-by":"crossref","first-page":"260","DOI":"10.17305\/bjbms.2010.2697","article-title":"Outcomes of 3% green tea emulsion on skin sebum production in male volunteers","volume":"10","author":"Mahmood","year":"2010","journal-title":"Bosn J Basic Med Sci"},{"issue":"1","key":"10.1111\/j.1529-8019.2012.01497.x-BIB62|cit62","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000067821","article-title":"Update and future of systemic acne treatment","volume":"206","author":"Zouboulis","year":"2003","journal-title":"Dermatology"},{"issue":"5","key":"10.1111\/j.1529-8019.2012.01497.x-BIB63|cit63","first-page":"271","article-title":"A status report on the medical management of rosacea: focus ontopical therapies","volume":"70","author":"Del Rosso","year":"2002","journal-title":"Cutis"},{"issue":"3","key":"10.1111\/j.1529-8019.2012.01497.x-BIB64|cit64","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/sder.2001.27553","article-title":"Rosacea: current thoughts on origin","volume":"20","author":"Bamford","year":"2001","journal-title":"Semin Cutan Med Surg"},{"issue":"3","key":"10.1111\/j.1529-8019.2012.01497.x-BIB65|cit65","first-page":"235","article-title":"Rosacea: pathogenesis and therapy","volume":"146","author":"Webster","year":"2011","journal-title":"G Ital Dermatol Venereol"},{"key":"10.1111\/j.1529-8019.2012.01497.x-BIB66|cit66","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1001\/archderm.1994.01690030091015","article-title":"Rosacea: pat hophysiology and treatment","volume":"130","author":"Wilkin","year":"1994","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1111\/j.1529-8019.2012.01497.x-BIB67|cit67","first-page":"531","article-title":"American Acne & Rosacea Society rosacea medical management guidelines","volume":"7","author":"Del Rosso","year":"2008","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"10.1111\/j.1529-8019.2012.01497.x-BIB68|cit68","first-page":"20","article-title":"Comprehensive medical management of rosacea: an interim study report and literature review","volume":"1","author":"Del Rosso","year":"2008","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1111\/j.1529-8019.2012.01497.x-BIB69|cit69","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/09546639709160276","article-title":"The treatment of rosacea: the safety and efficacy of sodium sulfacetamide 10% and sulfur 5% lotion is demonstrated in a double-blind study","volume":"8","author":"Sauder","year":"1997","journal-title":"J Dermatol Treat"},{"key":"10.1111\/j.1529-8019.2012.01497.x-BIB70|cit70","first-page":"183","article-title":"The comparative efficacy of sodium sulfacetamide 10%\/sulfur 5% lotion and metronidazole 0.75% gel in treatment of rosacea","volume":"3","author":"Lebwohl","year":"1995","journal-title":"J Dermatol Treat"},{"key":"10.1111\/j.1529-8019.2012.01497.x-BIB71|cit71","first-page":"553","article-title":"Successful treatment of rosacea with novel formulation of sodium sulfacetamide 10% and sulfur 5% topical lotion","volume":"18","author":"Davis","year":"1994","journal-title":"J Geriatr Dermatol"},{"key":"10.1111\/j.1529-8019.2012.01497.x-BIB72|cit72","unstructured":"Stweart D Assessment of tolerability of a prescription sodium sulfacetamide 10%\/sulfur 5% facial cleanser in adult subjects with rosacea 2001"},{"issue":"3","key":"10.1111\/j.1529-8019.2012.01497.x-BIB73|cit73","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/00128071-200001030-00007","article-title":"Topical Metronidazole: a review of its use in rosacea","volume":"1","author":"McClellan","year":"2000","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"10.1111\/j.1529-8019.2012.01497.x-BIB74|cit74","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/BF02850197","article-title":"Medication adherence: a key factor in effective management of rosacea","volume":"18","author":"Wolf","year":"2001","journal-title":"Adv Ther"},{"key":"10.1111\/j.1529-8019.2012.01497.x-BIB75|cit75","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jaad.2004.03.033","article-title":"Rosacea: II. Therapy","volume":"51","author":"Pelle","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1111\/j.1529-8019.2012.01497.x-BIB76|cit76","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1517\/14656566.5.1.5","article-title":"Medical treatment of rosacea with emphasis on topical therapies","volume":"5","author":"Del Rosso","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"10.1111\/j.1529-8019.2012.01497.x-BIB77|cit77","first-page":"1444","article-title":"Efficacy and safety of azelaic acid 15% gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled randomized phase III studies","volume":"139","author":"Thiboutot","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1111\/j.1529-8019.2012.01497.x-BIB78|cit78","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1001\/archderm.139.11.1444","article-title":"A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial","volume":"139","author":"Elewski","year":"2003","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1111\/j.1529-8019.2012.01497.x-BIB79|cit79","first-page":"97","article-title":"Update on rosacea pathogenesis and correlation with medical therapeutic agents","volume":"78","author":"Del Rosso","year":"2006","journal-title":"Cutis"},{"key":"10.1111\/j.1529-8019.2012.01497.x-BIB80|cit80","first-page":"AB30","article-title":"Multicenter, double-blind, randomized, placebo-controlled, parallel-group trial results evaluating the effects of 40\u2003mg doxycycline monohydrate controlled-release capsules in treatment of rosacea","volume":"54","author":"Del Rosso","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1529-8019.2012.01497.x-BIB81|cit81","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jaad.2006.11.021","article-title":"Two randomized, phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea","volume":"65","author":"Del Rosso","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1111\/j.1529-8019.2012.01497.x-BIB82|cit82","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1540-9740.2003.03014.x","article-title":"Subantimicrobial dose doxycycline for acne and rosacea","volume":"2","author":"Bikowski","year":"2003","journal-title":"Skinmed"},{"key":"10.1111\/j.1529-8019.2012.01497.x-BIB83|cit83","unstructured":"Oracea. Collagenex Pharmaceuticals, physician's desk reference 2007"},{"issue":"3","key":"10.1111\/j.1529-8019.2012.01497.x-BIB84|cit84","first-page":"21","article-title":"Rosacea subtypes: a treatment algorithm","volume":"74","author":"Dahl","year":"2004","journal-title":"Cutis"}],"container-title":["Dermatologic Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1529-8019.2012.01497.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1529-8019.2012.01497.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T17:58:42Z","timestamp":1671818322000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1529-8019.2012.01497.x"}},"subtitle":["New antibiotic therapies for acne and rosacea"],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":84,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1529-8019.2012.01497.x","relation":{},"ISSN":["1396-0296"],"issn-type":[{"value":"1396-0296","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}